Cone photoreceptor cell death as it occurs in certain hereditary retinal diseases is devastating, with the affected patients suffering from a loss of accurate and color vision. Regrettably, these hereditary cone diseases are still untreatable to date. Thus, the identification of substances able to block or restrain cone cell death is of primary importance. We studied the neuroprotective effects of a histone deacetylase inhibitor, Trichostatin A (TSA), in a mouse model of inherited, primary cone degeneration (cpfl1). We show that HDAC inhibition protects cpfl1 cones in vitro, in retinal explant cultures. More importantly, in vivo, a single intravitreal TSA injection significantly increased cone survival for up to 16 days postinjection. In addition, the abnormal, incomplete cone migration pattern in the cpfl1 retina was significantly improved by HDAC inhibition. These findings suggest a crucial role for HDAC activity in primary cone degeneration and highlight a new avenue for future therapy developments for cone dystrophies and retinal diseases associated with impaired cone migration.
Introduction
Cone photoreceptors in the human retina are responsible for sharp high resolution vision and color discrimination. Hereditary cone degenerations, such as in Stargardt´s and Best´s disease, achromatopsia, and cone dystrophies are caused by mutations in single genes, and lead to severe visual impairment, reduced visual acuity and loss of color vision. Cone dystrophies are characterized by a high genetic heterogeneity, with disease causing mutations in at least 27 genes (RetNet: https://sph.uth.edu/retnet). In addition, a genetic contribution has also been proposed for complex diseases affecting cones, such as in age-related-macular degeneration (AMD) or diabetic retinopathy (DR). Irrespective of the genetic cause, a common outcome of retinal diseases is neuronal cell death, giving a strong rationale for targeted neuroprotective approaches that may prevent or delay cell death execution (1).
The cone photoreceptor function loss-1 (cpfl1) mutant mouse is an animal model for autosomal recessive achromatopsia or progressive cone dystrophy (2). This model is unique in the sense that it is characterized by an early onset of cone loss at post-natal day 14 (PN14) and a fast progression with the peak of cell death at PN24 (3). We have previously shown that photoreceptor cell death in the cpfl1 mouse, as well as in nine other animal models for inherited retinal degeneration, follows a non-apoptotic mechanism, characterized by accumulation of cGMP, increased activities of cGMP-dependent protein kinase (PKG), histone deacetylase (HDAC), poly-ADP-ribose-polymerase (PARP), and calpain proteases, as well as accumulation of poly-ADP-ribose (PAR) (4, 5). In addition, the cpfl1 cone degeneration is also associated with prominent defects in cone migration (3).
A common non-apoptotic cell death mechanism in different retinal degeneration models provides a rationale for the identification of therapeutic targets that would prove beneficial for a broader population of patients suffering from a variety of different genetic causes (4, 6). While, numerous attempts to restrain the execution of rod photoreceptor cell death were described (6-11) to date, an effective clinical treatment for primary cone photoreceptor degeneration has not been reported. Since humans use mostly cones for at United Arab Emirates University on http://hmg.oxfordjournals.org/ Downloaded from their vision, a development of treatment protocols to preserve cones is of highest priority in clinical ophthalmology.
The interplay between histone acetylation and deacetylation, performed by histone acetyltransferases (HATs) and histone deacetylases (HDACs) respectively, determines the transcription state of genes in general (12) , and this is also true for photoreceptor-specific genes (13, 14) . Aberrant activity of histone deacetylases is associated with a number of diseases with very different etiology, ranging from cancer to neurodegenerative diseases (15) . Consequently, in current medicine, HDAC inhibition is discussed as one of the most promising novel therapeutic approaches for various diseases (16) .
In the present study, we tested the hypothesis that hereditary cone degeneration can be prevented or delayed by HDAC pharmacological inhibition. We assessed cone photoreceptor survival after HDAC inhibition with Trichostatin A (TSA) in vitro, on retinal explant cultures obtained from cpfl1 animals, as well as in vivo, after intravitreal injection. We show that TSA protects cpfl1 cones both in vitro and in vivo. Importantly, a single TSA injection in vivo achieved a significant protection of cone photoreceptors, up to sixteen days post-injection. In addition, we observed a significant improvement of impaired cone migration, present in the degenerating cpfl1 retina. Our study highlights the possibility to use pharmacological HDAC inhibition for substantial cone protection in an inherited cone dystrophy, and may forward the future development of therapies aimed at cone photoreceptor preservation.
Results

HDAC activity is increased in cpfl1 photoreceptors
We have previously shown that the cpfl1 cone photoreceptor degeneration follows a non-apoptotic cell death mechanism characterized by increased HDAC activity at the peak of degeneration at PN24 (4). In this study, we evaluated HDAC activity also at the onset of cone degeneration (PN14) and found significantly more HDAC activity positive photoreceptors in mutant retinas compared to wild-type (wt) (Supplementary material Fig. S1A 
HDAC inhibition with TSA rescues degenerating cones in vitro
To test whether HDAC inhibition could promote cone photoreceptor survival, we used cpfl1 long-term retinal explants cultured under entirely defined conditions, in serum-free medium. Both cpfl1 and wt retinas were explanted at the onset of cpfl1 degeneration (PN14) and cultured for 2 days in regular R16 retinal culture medium, without any treatment. Retinas were then exposed to 10 nM TSA every second day, until PN24. In the untreated cpfl1 explants almost half of the cones were lost at PN24, as assessed by the percentage of cones in the outer nuclear layer (ONL), identified by labeling with an antibody for glycogen phosphorylase (Glyphos) (17) . When compared to untreated wt explants (n=4), only ~53% of cones are still present in cpfl1 retina as shown in Figure 1 
Intravitreal TSA injection protects degenerating cones in vivo
These promising in vitro results prompted us to further evaluate the protective effects of HDAC inhibition in vivo. To guide and optimize the in vivo treatment scheme, we first tried to predict the potential half-life of the drug inside the eye. Model calculations suggested that intravitreal clearance of TSA in the rabbit eye was 0.478 ml/h, and the half-life was in the range of 1.7-3.3 hours. In the mouse, the calculated intravitreal half-life of TSA was an order of magnitude shorter (about 17 minutes), and more than 90% of the dose was expected to be eliminated in one hour after injection (Supplementary material Fig. S2 and Note 1).
Since our in vitro experiments suggested that 10 nM TSA was efficiently protecting cones, we wanted to test if the same concentration would be effective also in vivo. As controls, we included both non-treated and sham treated eyes in the analysis. At PN14, nine animals from three different litters received an injection of 0.5 µl of a 100 nM TSA solution in one eye, with an estimated final TSA concentration of 10 nM. The contralateral eyes were sham injected with vehicle to control for injection-specific effects. Mice were sacrificed and analyzed 10 days later, at PN24. Consistent with our in vitro results, TSA significantly increased the percentage of surviving cones in treated vs. sham treated eyes (cpfl1 sham: 84.92% ± 3.1 SEM, n=9; cpfl1 treated: 99.88% ± 4.83, n=9, p=0.026; Fig. 2 ). The percentage of cones in sham injected eyes was comparable to the percentage of cones in non-treated cpfl1 mice (cpfl1: 78.24% ± 2.53 SEM, n=8; cpfl1 sham: 84.92% ± 3.1, n=9), suggesting that the injection itself had no effect on cone survival. The number of cones in sham-or 10 nM TSA-treated wt retinas were similar to non-treated wt retinas confirming the in vitro observation that TSA in the studied dosage had no deleterious effect on healthy cones (wt sham: 102.37% ± 4.72, n=8; wt treated: 106.11% ± 7.02, n=8, Fig. 2 ). The in vivo results suggested a remarkable protection of degenerating cones by a single intravitreal injection of 10 nM TSA with the number of cones in treated retinas reaching 99.8% of wt levels. To then test if TSA could efficiently protect degenerating cones at even lower concentrations, we performed a single intravitreal injection of TSA with a final estimated concentration of 1 nM, at PN14, and evaluated the protective effects at PN24. Remarkably, 1 nM TSA single treatment yielded a protective effect comparable to the 10 nM dose (Fig. 2, cpfl1 sham: 83.24% ± 2.92 SEM, n=10; cpfl1 treated: 98.3% ± 5.25, n=11, p=0.03).
To assess protective effect of HDAC inhibition at longer time points, we treated the cpfl1 animals with a single intravitreal injection of 10 nM TSA and assessed cone survival at PN30, i.e. after the peak of degeneration. When compared to untreated PN30 wt retina, cone loss in sham-treated cpfl1 had progressed further, with 71.6% ± 3.77 cones remaining ( Fig. 3 ). In contrast, in 10 nM TSA treated eyes, even 16 days after a single intravitreal injection, the percentage of cones was significantly higher than in sham-treated, with 88.74% ± 2.79 cones still present (n=5, p=0.007). However, the protective effect at PN30 was less pronounced than at PN24, with the number of surviving cones lower than in wt retina (p=0.03).
To understand whether the observed increase in the cone numbers after TSA treatment was due to an indirect effect of a reduced clearance by microglia, we assessed the status of microglia using a staining against ionized-calcium-binding-adapter molecule 1 (IBA1) (18) . Although activated microglia appeared to be present to some extent in the different layers of the retina, we neither detected a microglial invasion Fig. S3 ). Alternatively, the protective effect of TSA might have been related to a delay of cone maturation in cpfl1 animals. To address this possibility, we also characterized the status of cone differentiation by looking at the expression and localization of M-and S-opsins, as well as cone-specific transducin (GNAT2), previously reported to be abnormally distributed in degenerating cones (19) .
Although M-opsin was seen in untreated cone outer segments, cpfl1 cones frequently showed opsin mislocalization to the cell body ( Fig. 4G , arrows) and synaptic terminals ( Fig. 4G, arrowheads ). S-opsin staining revealed short outer segments as well as opsin mislocalization (Fig. 4H , arrows) in untreated cpfl1 cones and a similar but more pronounced mislocalization was observed for GNAT2 ( Fig. 4I , arrows). In contrast, double staining for M-and S-opsin with Glyphos indicated that cones protected by TSA had normal morphology, with clearly developed inner and outer segments ( 
HDAC inhibition significantly improves impaired cone migration
We previously reported that cpfl1 retina is characterized by impaired migration of developing cones position very similar to that of wt cones (cpfl1 untreated: 55.31% ± 3.1 SEM, n=6; cpfl1 treated: 65.95% ± 2.8, p=0.029). Similarly, cone migration was also improved in cpfl1 retinas in vivo, after treatment with 1 nM TSA. Here, cones were localized significantly more distant from the outer plexiform layer (cpfl1 untreated: 71.68% ± 1.09 SEM, n=10, cpfl1 treated: 77.18% ± 0.84, n=11, p=0.02). Comparable results were obtained after treatment with 10 nM TSA (cpfl1 untreated: 67.47% ± 1.92 SEM, n=9, cpfl1 treated:
76.38% ± 0.73, n=9, p=0.0005). We did not observe changes in cone localization in wt retinas after TSA treatment (wt untreated: 86.89% ± 0.26 SEM, n=7; wt treated: 85.49% ± 0.23, n=7). Nevertheless, even though TSA treatment significantly improved cpfl1 cone migration, cone positioning was still significantly different compared to wt cones (cpfl1 1 nM TSA: 77.18% ± 0.84 SEM vs. wt untreated:
86.89% ± 0.26, p=0.0002; cpfl1 10nM: 76.38% ± 0.73 vs. wt untreated: 86.89% ± 0.26, p=0.0004).
We previously found high cGMP accumulation and increased activity of cGMP-dependent protein kinase G (PKG) to be associated with cpfl1 cone phenotypes (3). To investigate whether HDAC inhibition had an effect on cGMP and PKG activity after ten days of treatment with TSA, we looked for cGMP accumulation and the phosphorylation status of a well-known PKG substrate, vasodilatorstimulated-protein (pVASP) (20), with and without TSA treatment. Untreated cpfl1 retinas showed cGMP accumulation in cone segments as well as in cone cell bodies (as evidenced by Glyphos co-labeling).
There were no obvious differences in cone cGMP accumulation after TSA treatment. (Supplementary material Fig. S4A ). Likewise, some cones, visualized by Glyphos staining, were also positive for pVASP in both TSA treated and untreated cpfl1 retinas, with no evident differences between the two (Fig. S4B ).
Taken together, these results indicated that HDAC activity (and TSA inhibition) operated down-stream of the mutation-induced cGMP accumulation. HDAC inhibition was found to induce cell death in tumor cells derived from various cancers (21) , while in neurodegenerative diseases, the same treatment may prolong cell survival (22) . In the retina, HDAC inhibitors have been discussed as a potential therapeutic strategy for ischemic retinal injury, with different HDAC inhibitors affording structural and functional neuroprotection after experimental ischemia (23) . Furthermore, HDAC inhibition was shown to slow rod photoreceptor degeneration in an animal model for Retinitis Pigmentosa (24) . Importantly, current clinical trials are suggesting beneficial effects of treatments with a HDAC inhibitor in patients suffering from Retinitis Pigmentosa (25, 26) . We show here for the first time that HDAC inhibition significantly protects cones in a mouse model for hereditary cone dystrophy. Besides its implication for future treatment of rare forms of retinal degeneration, the results presented here may also extend to common diseases of the retina, including DR and AMD, where cone degeneration is the cause of legal blindness.
Discussion
An important result from our study is that a single intraocular application significantly protected cpfl1 cones for at least two weeks post-injection. This is unexpected, as our calculations on TSA clearance suggested that the drug was below threshold concentration, after less than 2 hours and may point to an imprinting mechanism, beyond the transient presence of TSA. This is in line with previous studies which found that TSA leads to robust protein acetylation after 3 hours (13) or to transcriptional changes after only 5 minutes (27) , supporting the possibility of epigenetic mechanisms. The molecular mechanism underlying treatments with HDAC inhibitors are still not well characterized. In cpfl1 retina, a previous study found an upregulation of STAT3 signaling which was suggested as an endogenous neuroprotective response (28) . Interestingly, STAT3 activation may be controlled by HDAC activity (29) .
at United Arab Emirates University on http://hmg.oxfordjournals.org/ Downloaded from Importantly, the TSA clearance estimation suggested that cone degeneration was halted already after a short-time intraocular exposure. This observation could be especially relevant for patients with retinal dystrophies where monthly intravitreal injections are usually well tolerated (30) . Since in mice the protective effect was present for at least 10 days post-injection, a rough extrapolation from mouse to man, would suggest that in humans an intravitreal dosing once per three months might be sufficient (31) .
Alternatively, formulations for local application to the eye would minimize the potential side-effects observed in some cases of long-term, systemic HDAC inhibition (26, 32, 33) .
Cone photoreceptor development is characterized by a migration within the ONL, from the outer limiting membrane inwards to the OPL, and then outwards, until they reach their final position just below the outer limiting membrane, from PN12 onwards (34) . Cone degeneration in mouse models is characterized not only by cone loss, but also by improper developmental cone migration (3, 35) . In fact, delayed cone migration was also reported in mouse models with rod degeneration as an indirect consequence of rod cell death (34) . Migration of cone photoreceptors also occurs in human retinal development, where in the fovea cones are migrating laterally towards the foveal pit (36) . Cone misplacement has been associated with human retinal diseases of different etiology as improper cone migration can lead to foveal hypoplasia (37) . This is observed, for instance, in patients suffering from albinism (38) , idiopathic congenital nystagmus (37) , and also from achromatopsia (39) . In addition, cone misplacement was reported in aged patients suffering from AMD (40). We found that TSA treatment not only prevented cone degeneration but also significantly improved aberrant cone migration in degenerating cpfl1 retina. There are numerous reports on the effects of HDAC inhibition on cell migration. The effects of HDAC inhibition on improved cell migration could take place via inhibition of the cytoplasmic histone deacetylase (HDAC6) resulting in higher acetylation of α-tubulin necessary for stability of microtubules in migrating cells (41) . Alternatively, HDAC inhibition could lead to epigenetic changes governing migration of photoreceptors, a process still not fully understood. TSA treatment significantly improved the migration of misplaced cpfl1 cones both in vitro and in vivo. Nevertheless, HDAC inhibition alone was not sufficient to fully repair the cone migration defect in cpfl1 retinas. A plausible explanation could relate to increased PKG activity in cpfl1 retina, as we previously reported (3). PKG-specific phosphorylation of the serine 239 residue of VASP was shown to negatively regulate neuronal migration (42) . Proteins of the Ena/VASP family are regulators of actin assembly and cell motility as they are localized in focal adhesions (43) . cGMP-dependent PKG overactivation leads to VASP phosphorylation, which will result in removal of VASP from focal adhesions, contributing to altered cell migration (44) .
Our data suggest that TSA inhibition of HDACs did not reduce VASP phosphorylation of serine 239 as found that increased PKG and HDAC activities were temporally connected in 10 different animal models for inherited retinal degeneration (4). This corresponds to observations in C. elegans where PKG activity was found to regulate HDAC activation (48) . Since HDAC inhibition did not seem to affect VASP phosphorylation in cones, our study indicates that during cell death HDAC activity may occur independently of-or downstream of PKG. The underlying mechanisms through which HDAC inhibition offers cone protection remains to be determined.
HDAC activity is also crucial for mouse photoreceptor development as HDAC inhibition at early postnatal retinal development (PN2) leads to a complete loss of developing rod photoreceptors (49) . In the mouse retina cone photoreceptors are born prenatally (45), therefore we do not expect an effect of TSA on cone birth, but the full maturation and commitment towards blue cones (S cones) or red/green cones (M cones) takes place during the second postnatal week (50) . Since we performed HDAC inhibition just after this time-period, we assessed the expression and localization of S-and M-opsin, to address whether the observed increase in cone survival following HDAC inhibition was due to cone development and maturation delays. In addition, we checked for the cone specific transducin (GNAT2), a member of the cone phototransduction cascade (51) . The observed correct localization of cone opsins and transducin suggests that late postnatal HDAC inhibition did not affect cone cell development and maturation.
However, we cannot exclude the possibility that the rapid degeneration of cpfl1 cones was in part caused by developmental defects. In this case TSA treatment, in a critical time-frame, may have supported normal development as the observed effects lasted for more than two weeks. Future studies, for instance on more slowly progressing cone degeneration models, may reveal whether TSA and HDAC inhibition mediated cone protection can be applied to cone degeneration in general, irrespective of developmental stage and disease pathogenesis.
In summary, this study is the first to show that HDAC inhibition can significantly delay cone loss in a mouse model for a human cone dystrophy. While the effect of TSA on cpfl1 retina in vivo lasts until at least one month post-natal, further studies will be needed to determine the duration of the protection and to establish long-term treatment paradigms. Remarkably, HDAC inhibition appeared to have a dual effect on both cone survival and cone migration without obvious effects on cone differentiation and development. Our study thus provides a proof-of-principle for the potential of HDAC inhibitors as therapeutic agents for cone photoreceptor protection. Importantly, this may be applicable not only to hereditary cone dystrophies, but possibly also to common retinal diseases associated with cone degeneration such as diabetic retinopathy (52, 53) , as well to diseases where cone degeneration is accompanied by improper cone migration, such as age-related macular degeneration (40). Supplementary Fig. S5 ), a well-established marker for cones (55) . Supplementary Fig.S1E ).
Retinal explant cultures
Organotypic retinal cultures from cpfl1 (n=7) and wt (n=4) animals that included the retinal pigment epithelium (RPE) were prepared under sterile conditions. Briefly, PN14 animals were sacrificed, the eyes enucleated and pretreated with 0.12% proteinase K (ICN Biomedicals Inc., OH, USA) for 15 minutes at 37°C in R16 serum free culture medium (Order No.: 074-90743A; Gibco, Paisley, UK). Proteinase K activity was blocked by addition of 10% fetal bovine serum, followed by rinsing in serum-free medium.
Following this, the cornea, lens, sclera and choroid were removed carefully, with only the RPE remaining attached to the retina. The explant was then cut into four wedges, to give a clover-leaf like structure, which was transferred to a culture membrane insert (Corning Life Sciences, Lowell, USA) with the RPE facing the membrane. The membrane inserts were placed into six well culture plates with R16 medium (Gibco, Paisley, UK) and incubated at 37°C in a humidified 5% CO 2 incubator. The culture medium was changed every 2 days during the 10 culturing days.
Retinal explants were left without treatment for 2 days (until PN16), followed by 10 nM Trichostatin A (TSA) treatment (≥98% (HPLC), from Streptomyces sp., Sigma-Aldrich, St-Louis, USA). TSA was dissolved in 0.2% dimethyl sulfoxide (DMSO; Sigma) and diluted in R16 culture medium. For controls, the same amount of DMSO was diluted in culture medium. Culturing was stopped at PN24 by 2 h fixation in 4% PFA, cryoprotected with graded sucrose solutions containing 10, 20, and 30% sucrose and then embedded in tissue freezing medium (Leica Microsystems Nussloch GmbH, Nussloch, Germany).
In vivo injections
Animals were anesthetized with an intraperitoneal injection of Avertin (250 mg/kg) (1.25% (w/v) 2,2,2-tribromoethanol and 2.5% (v/v) 2-methyl-2-butanol; Sigma, Milan, IT) and kept warm during injections. Single intravitreal injections were performed at PN14 on one eye while the other eye was sham injected with 0.0001% DMSO (in 0.9% NaCl solution) as contralateral control. TSA (1 and 10 nM) was diluted in 0.9% NaCl solution. Injections were performed with 0.5 µl of 10 nM and 100 nM TSA in order to have a final concentration of 1 nM and 10 nM, respectively, assuming the free intraocular volume of mouse eye to be 5µl (http://prometheus.med.utah.edu/~marclab/protocols.html). Eleven cpfl1 animals and eight wt from three different litters were used for intravitreal injections and were sacrificed 10 days after treatment (PN24). For the treatment of cpfl1 animals until PN30 injections were performed at PN14 in five different animals with one eye being injected with 10 nM TSA, while the other eye was sham injected. Eyes were immediately enucleated, fixed for 2 h in 4% PFA and prepared for cryosectioning (see 'Retinal explant cultures'). Sections were labeled in a non-conclusive fashion to allow for an investigator-blind analysis. Supplementary Fig. S2 ). Compounds that lie inside the ellipse depicted in the plot belong to the same chemical space of the model and are predictable by the model. Once the applicability domain was confirmed, the intravitreal clearance value of TSA was calculated with the above equation using the descriptors values (LogD at pH 7.4 and HD). Half-life was calculated using equation t 1/2 = ln2 V d /CL, where V d is the volume of distribution and CL is the intravitreal clearance. For a brief discussion on the transferability between rabbit and mouse data, see supplementary note 1. 
Microscopy, cell counting, and statistical analysis
